Analysis of 313 transplantations from unrelated donors facilitated by Japan Marrow Donor Program

Y. Kodera, Y. Morishima, S. Kato, M. Harada, H. Dohi, S. Qkamoto, H. Imamura, S. Tsuchiya, Y. Moriyama, H. Kodo, M. Tsuchida, Y. Hoshi, S. Shiobara, K. Horibe, H. Shibata, A. Kanaaaru, Y. Akiyama, H. Gondo, J. Okaaura, S. AsanonT. Juji, Takehiko Sasazuki, F. Takaku

Research output: Contribution to journalArticle

Abstract

In December 1991, Japan Marrow Donor Pragran (JMBP) was created in the cooperation of Japanese Red Cross and Japan Marrow Donor Foundation under the control of The Ministry of Health and Welfare in Japan, and by February 1995. 70.282 HU-A.B-typed volunteer marrow donors and 3.824 patients were registered to JMDP. The results of Hl,A-matching between the donors and the patients revealed that 2,588 out of 3.755 (69%) patients could have HLA-A.B.DR Hatched donors and among these watched pairs. 674 unrelated bone marrow transplantations IUBMT) were performed.The initial 313 UBMT transplanted from January 1993 to March 1995 were analysed as of October 1995. Erigraftaent was achieved at 96% of the cases. The probability of Grade-U . III. IV acute GVHD was 38% and that of Grade-ID. IV was 20%. The rate of disease-free survival (DPS) at two years anong patients with aplastic anenia(37 cases)was 61 % and anting the patients with acute myelogenous leukeiia in the 1st complete remission(tCR). 2-3CR and non-CR were 72%.60 and OX respectively. The rate of DPS among the patients with acute lynphocytic leukemia in ICR.2-3CR and non-CR were 685K. 32% and 33%.Two-years DPS of chronic myelogenous leukemia in chronic phase(CP). accerelated phase or 2nd CP and blastic crisis were 41%. 48% and 0%. It can be stated that UBNT is a modality of treatment which is as effective as related BMT aaong Japanese, although the control of acute GVHD is especially a subject for further investigation.

Original languageEnglish
Number of pages1
JournalExperimental Hematology
Volume24
Issue number9
Publication statusPublished - Dec 1 1996
Externally publishedYes

Fingerprint

Unrelated Donors
Japan
Transplantation
Bone Marrow
Tissue Donors
Leukemia, Myeloid, Chronic Phase
Red Cross
Bone Marrow Transplantation
Disease-Free Survival
Volunteers
Leukemia
Health

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Hematology
  • Genetics
  • Cell Biology
  • Cancer Research

Cite this

Kodera, Y., Morishima, Y., Kato, S., Harada, M., Dohi, H., Qkamoto, S., ... Takaku, F. (1996). Analysis of 313 transplantations from unrelated donors facilitated by Japan Marrow Donor Program. Experimental Hematology, 24(9).

Analysis of 313 transplantations from unrelated donors facilitated by Japan Marrow Donor Program. / Kodera, Y.; Morishima, Y.; Kato, S.; Harada, M.; Dohi, H.; Qkamoto, S.; Imamura, H.; Tsuchiya, S.; Moriyama, Y.; Kodo, H.; Tsuchida, M.; Hoshi, Y.; Shiobara, S.; Horibe, K.; Shibata, H.; Kanaaaru, A.; Akiyama, Y.; Gondo, H.; Okaaura, J.; Asanon, S.; Juji, T.; Sasazuki, Takehiko; Takaku, F.

In: Experimental Hematology, Vol. 24, No. 9, 01.12.1996.

Research output: Contribution to journalArticle

Kodera, Y, Morishima, Y, Kato, S, Harada, M, Dohi, H, Qkamoto, S, Imamura, H, Tsuchiya, S, Moriyama, Y, Kodo, H, Tsuchida, M, Hoshi, Y, Shiobara, S, Horibe, K, Shibata, H, Kanaaaru, A, Akiyama, Y, Gondo, H, Okaaura, J, Asanon, S, Juji, T, Sasazuki, T & Takaku, F 1996, 'Analysis of 313 transplantations from unrelated donors facilitated by Japan Marrow Donor Program', Experimental Hematology, vol. 24, no. 9.
Kodera Y, Morishima Y, Kato S, Harada M, Dohi H, Qkamoto S et al. Analysis of 313 transplantations from unrelated donors facilitated by Japan Marrow Donor Program. Experimental Hematology. 1996 Dec 1;24(9).
Kodera, Y. ; Morishima, Y. ; Kato, S. ; Harada, M. ; Dohi, H. ; Qkamoto, S. ; Imamura, H. ; Tsuchiya, S. ; Moriyama, Y. ; Kodo, H. ; Tsuchida, M. ; Hoshi, Y. ; Shiobara, S. ; Horibe, K. ; Shibata, H. ; Kanaaaru, A. ; Akiyama, Y. ; Gondo, H. ; Okaaura, J. ; Asanon, S. ; Juji, T. ; Sasazuki, Takehiko ; Takaku, F. / Analysis of 313 transplantations from unrelated donors facilitated by Japan Marrow Donor Program. In: Experimental Hematology. 1996 ; Vol. 24, No. 9.
@article{830814f143ae4aa4a45e475cf430b482,
title = "Analysis of 313 transplantations from unrelated donors facilitated by Japan Marrow Donor Program",
abstract = "In December 1991, Japan Marrow Donor Pragran (JMBP) was created in the cooperation of Japanese Red Cross and Japan Marrow Donor Foundation under the control of The Ministry of Health and Welfare in Japan, and by February 1995. 70.282 HU-A.B-typed volunteer marrow donors and 3.824 patients were registered to JMDP. The results of Hl,A-matching between the donors and the patients revealed that 2,588 out of 3.755 (69{\%}) patients could have HLA-A.B.DR Hatched donors and among these watched pairs. 674 unrelated bone marrow transplantations IUBMT) were performed.The initial 313 UBMT transplanted from January 1993 to March 1995 were analysed as of October 1995. Erigraftaent was achieved at 96{\%} of the cases. The probability of Grade-U . III. IV acute GVHD was 38{\%} and that of Grade-ID. IV was 20{\%}. The rate of disease-free survival (DPS) at two years anong patients with aplastic anenia(37 cases)was 61 {\%} and anting the patients with acute myelogenous leukeiia in the 1st complete remission(tCR). 2-3CR and non-CR were 72{\%}.60 and OX respectively. The rate of DPS among the patients with acute lynphocytic leukemia in ICR.2-3CR and non-CR were 685K. 32{\%} and 33{\%}.Two-years DPS of chronic myelogenous leukemia in chronic phase(CP). accerelated phase or 2nd CP and blastic crisis were 41{\%}. 48{\%} and 0{\%}. It can be stated that UBNT is a modality of treatment which is as effective as related BMT aaong Japanese, although the control of acute GVHD is especially a subject for further investigation.",
author = "Y. Kodera and Y. Morishima and S. Kato and M. Harada and H. Dohi and S. Qkamoto and H. Imamura and S. Tsuchiya and Y. Moriyama and H. Kodo and M. Tsuchida and Y. Hoshi and S. Shiobara and K. Horibe and H. Shibata and A. Kanaaaru and Y. Akiyama and H. Gondo and J. Okaaura and S. Asanon and T. Juji and Takehiko Sasazuki and F. Takaku",
year = "1996",
month = "12",
day = "1",
language = "English",
volume = "24",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Analysis of 313 transplantations from unrelated donors facilitated by Japan Marrow Donor Program

AU - Kodera, Y.

AU - Morishima, Y.

AU - Kato, S.

AU - Harada, M.

AU - Dohi, H.

AU - Qkamoto, S.

AU - Imamura, H.

AU - Tsuchiya, S.

AU - Moriyama, Y.

AU - Kodo, H.

AU - Tsuchida, M.

AU - Hoshi, Y.

AU - Shiobara, S.

AU - Horibe, K.

AU - Shibata, H.

AU - Kanaaaru, A.

AU - Akiyama, Y.

AU - Gondo, H.

AU - Okaaura, J.

AU - Asanon, S.

AU - Juji, T.

AU - Sasazuki, Takehiko

AU - Takaku, F.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - In December 1991, Japan Marrow Donor Pragran (JMBP) was created in the cooperation of Japanese Red Cross and Japan Marrow Donor Foundation under the control of The Ministry of Health and Welfare in Japan, and by February 1995. 70.282 HU-A.B-typed volunteer marrow donors and 3.824 patients were registered to JMDP. The results of Hl,A-matching between the donors and the patients revealed that 2,588 out of 3.755 (69%) patients could have HLA-A.B.DR Hatched donors and among these watched pairs. 674 unrelated bone marrow transplantations IUBMT) were performed.The initial 313 UBMT transplanted from January 1993 to March 1995 were analysed as of October 1995. Erigraftaent was achieved at 96% of the cases. The probability of Grade-U . III. IV acute GVHD was 38% and that of Grade-ID. IV was 20%. The rate of disease-free survival (DPS) at two years anong patients with aplastic anenia(37 cases)was 61 % and anting the patients with acute myelogenous leukeiia in the 1st complete remission(tCR). 2-3CR and non-CR were 72%.60 and OX respectively. The rate of DPS among the patients with acute lynphocytic leukemia in ICR.2-3CR and non-CR were 685K. 32% and 33%.Two-years DPS of chronic myelogenous leukemia in chronic phase(CP). accerelated phase or 2nd CP and blastic crisis were 41%. 48% and 0%. It can be stated that UBNT is a modality of treatment which is as effective as related BMT aaong Japanese, although the control of acute GVHD is especially a subject for further investigation.

AB - In December 1991, Japan Marrow Donor Pragran (JMBP) was created in the cooperation of Japanese Red Cross and Japan Marrow Donor Foundation under the control of The Ministry of Health and Welfare in Japan, and by February 1995. 70.282 HU-A.B-typed volunteer marrow donors and 3.824 patients were registered to JMDP. The results of Hl,A-matching between the donors and the patients revealed that 2,588 out of 3.755 (69%) patients could have HLA-A.B.DR Hatched donors and among these watched pairs. 674 unrelated bone marrow transplantations IUBMT) were performed.The initial 313 UBMT transplanted from January 1993 to March 1995 were analysed as of October 1995. Erigraftaent was achieved at 96% of the cases. The probability of Grade-U . III. IV acute GVHD was 38% and that of Grade-ID. IV was 20%. The rate of disease-free survival (DPS) at two years anong patients with aplastic anenia(37 cases)was 61 % and anting the patients with acute myelogenous leukeiia in the 1st complete remission(tCR). 2-3CR and non-CR were 72%.60 and OX respectively. The rate of DPS among the patients with acute lynphocytic leukemia in ICR.2-3CR and non-CR were 685K. 32% and 33%.Two-years DPS of chronic myelogenous leukemia in chronic phase(CP). accerelated phase or 2nd CP and blastic crisis were 41%. 48% and 0%. It can be stated that UBNT is a modality of treatment which is as effective as related BMT aaong Japanese, although the control of acute GVHD is especially a subject for further investigation.

UR - http://www.scopus.com/inward/record.url?scp=33748596857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748596857&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748596857

VL - 24

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 9

ER -